NLST has become one of the more striking stories in US small-cap markets this summer: a stock up 183% in a month, with short sellers quietly reducing their exposure even as the price accelerates away from them.
The short-side story here is genuinely unusual. Short interest has fallen by nearly a third over the past month, dropping from around 36.7 million shares in late July to 25.1 million now — 8.2% of the free float. That monthly decline of 32% in short shares is a meaningful retreat, not just noise. The weekly picture softens the story slightly: a 17% drop week-on-week, followed by a tiny tick up of 0.6% on September 1. The direction of travel, though, is unmistakably lower. Shorts have been covering into the rally rather than adding. Borrow conditions reinforce that reading: cost to borrow has halved over the past month to around 5.5%, down sharply from levels above 10% that prevailed through most of July and early August. Availability is now at 159% — roughly one and a half shares available to borrow for every share already lent out — a far looser lending market than the 2.3% minimum recorded at some point in the past year. The squeeze pressure that may have driven earlier covering has largely released.
Where the ORTEX short score adds texture is in its recent movement. The score climbed to 75 on September 1 — elevated, but notably below the 80 reading registered on August 24. That peak coincided almost exactly with the point at which short interest was highest and cost to borrow was still running above 8%. The score has since eased alongside the covering. It remains in high territory, ranking in just the 2nd percentile of the ORTEX universe on short score — meaning most stocks carry less short pressure than NLST — but the trend is softening rather than intensifying.
The fundamental picture is harder to anchor. Valuation multiples are largely stale — the price-to-earnings and price-to-book figures carry data as old as 2020, when the company was loss-making, and they remain deeply negative. There is no meaningful Street coverage to triangulate against. The most recent analyst action on record is a Roth MKM price target cut to $2 from October 2024 — nearly a year old and filed when the stock was trading at a fraction of its current $6.65. A $15 mean price target appears in the data but cannot be reliably reconciled with the coverage history available; treat it as indicative at best. What the factor scores do confirm is that momentum is the dominant driver: ORTEX's stock score, last formally computed in July, showed a perfect momentum pillar reading, with the quality and value dimensions deeply suppressed. This is a momentum-driven name, not a fundamental rerating.
Earnings history adds a sharp dimension to the setup. The August 11 print produced a 22% single-day gain and a 59% five-day move — numbers that suggest this stock reacts violently to catalysts. The July 30 event saw a 4% drop on the day but a 56% five-day gain. The next scheduled event is October 27. Between now and then, the stock has moved from under $2 to $6.65 — a 183% monthly run — while short sellers have been steadily walking away from the trade. The institutional holder list is thin: the largest holder, Chun Hong at 2.8%, has not changed their position recently. CEO Chun K Hong's most recent open-market trades on record were 10b5-1 plan sales in January 2026 at $1.00 — well below the current price, and now eight months stale.
The question heading into October is whether the covering flow that drove much of the rally has run its course, or whether the remaining 8% short float continues to unwind — and what, if anything, connects this move to the October earnings date.
See the live data behind this article on ORTEX.
Open NLST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
